Sorrento Therapeutics (SRNE) Insider Trading & Ownership $0.0008 0.00 (-33.33%) (As of 12/20/2024 05:32 PM ET) Add Compare Share Share Insider Trades Stock AnalysisChartCompetitorsFinancialsInsider TradesOptions ChainSEC FilingsSustainabilityTrends Sorrento Therapeutics (NASDAQ:SRNE) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage2.60%Number OfInsiders Buying(Last 3 Years)1Amount OfInsider Buying(Last 3 Years)$59,777.32Number OfInsiders Selling(Last 3 Years)1Amount OfInsider Selling(Last 3 Years)$17,640.00 Get SRNE Insider Trade Alerts Want to know when executives and insiders are buying or selling Sorrento Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address SRNE Insider Buying and Selling by Quarter Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Sorrento Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/25/2022Henry JiInsiderBuy22,222$2.06$45,777.32 6/14/2022Henry JiInsiderBuy10,000$1.40$14,000.00 12/27/2021Kim JandaDirectorSell3,000$5.88$17,640.00 (Data available from 1/1/2013 forward) SRNE Insider Trading Activity - Frequently Asked Questions Who is on Sorrento Therapeutics's Insider Roster? The list of insiders at Sorrento Therapeutics includes Henry Ji, and Kim Janda. Learn more on insiders at SRNE. What percentage of Sorrento Therapeutics stock is owned by insiders? 2.60% of Sorrento Therapeutics stock is owned by insiders. Learn more on SRNE's insider holdings. Sorrento Therapeutics Key ExecutivesDr. Henry H. Ji Ph.D. (Age 60)Chairman, President & CEO Compensation: $2.03MDr. Scott SchausChief Technology Officer More Insider Trading Tools from MarketBeat Related Companies Cyclacel Pharmaceuticals Insider Trading Salarius Pharmaceuticals Insider Trading 180 Life Sciences Insider Trading Virpax Pharmaceuticals Insider Trading Galera Therapeutics Insider Trading Eterna Therapeutics Insider Trading Oncternal Therapeutics Insider Trading Panbela Therapeutics Insider Trading Revelation Biosciences Insider Trading Trevena Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles AppLovin Insiders Sell Shares: Stock Price Indicated Higher Are 2024’s Top Insider Buys a Good Bet for 2025? Bargains Galore? 3 Stocks With Insider Buying in the MillionsInsiders Keep Buying These Stocks: 2 to Buy, 1 to AvoidZeta Global Holdings Insiders Buy Stock After Short-Report This page (NASDAQ:SRNE) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sorrento Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sorrento Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SRNE Stock Alerts